NCT04740996 2022-02-07
Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
ChineseAMS
Unknown
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
ChineseAMS
PIMERIndia